top of page
Browse by category
Search
MC4R Agonist bremelanotide co-administered with tirzepatide meets primary endpoint
Palatin Technologies’ BMT-801 Phase 2 obesity co-administered melanocortin-4 receptor (MC4R) agonist bremelanotide plus glucagon like...
Palatin completes Phase 2 obesity study with MC4R bremelanotide + Tirzepatide
Palatin Technologies has completed its Phase 2 BMT-801 clinical study of the co-administration of MC4R bremelanotide + GLP-1/GIP...
Palatin completes study enrolment of bremelanotide plus tirzepatide to treat obesity
Palatin Technologies has completed enrolment in the study entitled "BMT-801, A Phase II, Randomized, Double-Blind, Placebo-Controlled,...
Palatin initiates study of bremelanotide for the treatment of obesity
Palatin Technologies has begun a Phase 2 clinical study of bremelanotide for the treatment of obesity. The clinical study will evaluate...
Browse by tag
bottom of page